Tag: Mounjaro
Post CDSCO approval, Lilly launches Mounjaro, a first of its kind...
The drug delivers superior A1C reductions versus all comparators in phase 3 SURPASS clinical trials
Eli Lilly’s Tirzepatide approved by NMPA in China, boosting market position
Tirzepatide’s debut as the first dual GIP and GLP-1 receptor agonist for obesity in China strengthens Eli Lilly’s presence
Viking Therapeutics’ obesity drug VK2735 could rival Eli Lilly’s Tirzepatide, says...
New Phase IIa results reveal significant weight loss, positioning VK2735 as a potential market leader amid increasing competition